Core-shell particle formulation for delivering multiple therapeutic agents

Abstract

A core-shell particle formulation for delivering multiple therapeutic agents is disclosed. More particularly, core-shell particle formulation configured to independently release therapeutic agents from the core and the shell. Moreover, the core-shell particle bearing therapeutic agents enables treatment against the diseases such as cancer, inflammatory and auto-immune diseases.

What is claimed is: 
     
         1 . A core-shell particle formulation for delivering multiple therapeutic agents comprising:
 one or more polymers forming a core, wherein the one or more polymers forming the core comprise poly(lactic-co-glycolic acid); and   one or more proteins forming a shell encapsulating the core to form a particle formulation, wherein the one or more proteins forming the shell comprise serum albumin;   wherein the core and the shell each comprise one or more therapeutic agents;   wherein the particle formulation is configured to independently release the therapeutic agents from the core and the shell; and   wherein the therapeutic agents are configured to be delivered by active targeting, wherein the active targeting is done by conjugating the core-shell formulation with transferrin ligand or EGFR.   
     
     
         2 . The formulation of  claim 1 , wherein the one or more therapeutic agents of the core comprise doxorubicin and the one or more therapeutic agents of the shell comprise sorafenib. 
     
     
         3 . The formulation of  claim 1 , wherein the one or more therapeutic agents of the core comprise sorafenib and the one or more therapeutic agents of the shell comprise doxorubicin. 
     
     
         4 . The formulation of  claim 1 , wherein the one or more therapeutic agents of the core comprise dasatinib and the one or more therapeutic agents of the shell comprise sorafenib. 
     
     
         5 . The formulation of  claim 1 , wherein the one or more therapeutic agents of the core comprise sorafenib and the one or more therapeutic agents of the shell comprise dasatinib. 
     
     
         6 . The formulation of  claim 1 , wherein the core is of average size ≦500 nm. 
     
     
         7 . The formulation of  claim 1 , wherein the shell is of average thickness ≦200 nm. 
     
     
         8 . The formulation of  claim 1 , wherein the therapeutic agents are configured to be delivered from the shell and core sequentially. 
     
     
         9 . The formulation of  claim 1 , wherein the therapeutic agents are configured to be delivered from the shell and core simultaneously. 
     
     
         10 . A core-shell particle formulation for delivering multiple therapeutic agents comprising:
 one or more polymers forming a core, wherein the one or more polymers forming the core comprise poly vinyl alcohol; and   one or more proteins forming a shell encapsulating the core to form a particle formulation, wherein the one or more proteins forming the shell comprise protamine;   wherein the core and the shell each comprise one or more therapeutic agents;   wherein the particle formulation is configured to independently release the therapeutic agents from the core and the shell; and   wherein the therapeutic agents are configured to be delivered by active targeting, wherein the active targeting is done by conjugating the core-shell formulation with transferrin ligand or EGFR.   
     
     
         11 . The formulation of  claim 10 , wherein the one or more therapeutic agents of the core comprise doxorubicin and the one or more therapeutic agents of the shell comprise sorafenib. 
     
     
         12 . The formulation of  claim 10 , wherein the one or more therapeutic agents of the core comprise sorafenib and the one or more therapeutic agents of the shell comprise doxorubicin. 
     
     
         13 . The formulation of  claim 10 , wherein the one or more therapeutic agents of the core comprise dasatinib and the one or more therapeutic agents of the shell comprise sorafenib. 
     
     
         14 . The formulation of  claim 10 , wherein the one or more therapeutic agents of the core comprise sorafenib and the one or more therapeutic agents of the shell comprise dasatinib. 
     
     
         15 . The formulation of  claim 10 , wherein the core is of average size ≦500 nm. 
     
     
         16 . The formulation of  claim 10 , wherein the shell is of average thickness ≦200 nm. 
     
     
         17 . The formulation of  claim 10 , wherein the therapeutic agents are configured to be delivered from the shell and core sequentially. 
     
     
         18 . The formulation of  claim 10 , wherein the therapeutic agents are configured to be delivered from the shell and core simultaneously.